Cognitive Dysfunction clinical trials at UCSD
2 in progress, 0 open to eligible people
Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Sorry, not yet accepting patients
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
La Jolla, California and other locations
Improving Cognition After Cancer
Sorry, in progress, not accepting new patients
This study will test whether a physical activity intervention can improve cognition in breast cancer survivors and help the development of physical activity guidelines for cognition in breast cancer survivors.
La Jolla, California
Our lead scientists for Cognitive Dysfunction research studies include Stephanie Lessig Sheri Hartman.
Last updated: